2022-10-18| Policy

FDA Drops New Oncology Development Guidelines

by Reed Slater
Share To
Concept word 'FDA' on cubes on a beautiful wooden table. White background. Business concept. Copy space.
The FDA released a trio of documents covering tissue-agnostic development, adverse reactions caused by immunotherapies, and acute myeloid leukemia (AML) development guidelines to maintain high drug development standards. The first two documents are additional drafts, revising content from years prior, and the AML development document is a final version, though all three include nonbinding recommendations. 
Tissue-Agnostic Drug Development in Oncology

Instead of targeting a specific cancer type isolated in a certain tissue or organ, tissue-agnostic therapies can target mutation alterations across multiple cancer types. Tissue-agnostic cancer drugs have the potential to be more flexible for patient needs and open the opportunity to address several cancer types as opposed to just one.

It's free! Log in now to read

Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
Moderna Welcomes Phase 3 Win For RSV Vaccine
Moving Beyond COVID With mRNA Technology
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!